2026
conference-abstract
OpenAlex
Zuen Ren, Tiziano Bernasocchi, Kiran Kurmi, Chenxu Guo et autres
Abstract Chemoresistance is a primary cause of relapse and mortality in triple-negative breast cancer (TNBC). To reveal the metabolic characteristics that contribute to de novo chemoresistance in human TNBC, we analyzed primary tumor biopsies prior to preoperative chemotherapy, employing quantitative mass spectrometry-based …
us
(code pays fourni par la source)
Accès ouvert
2026
preprint
OpenAlex
Zuen Ren, Tiziano Bernasocchi, Kiran Kurmi, Chenxu Guo et autres
Abstract Chemoresistance is the leading cause of poor prognosis in triple-negative breast cancer (TNBC), yet the underlying mechanisms remain unknown. To reveal metabolic drivers of de novo chemoresistance in TNBC, we analyzed pretreatment primary tumor biopsies, employing quantitative proteomics and metabolomics. Chemoresistant …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Malalage Nicole Peiris, Aylin S. Dedeoglu, Ilze Smidt, Akiko Suzuki et autres
Breast cancer disparities in outcomes remain a persistent challenge in the USA, with survival influenced by neighborhood context, access to resources, and the applicability of existing scientific evidence across populations. These disparities arise from complex, intersectional factors spanning social, structural, and biologic …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Zuen Ren, Siang‐Boon Koh, Kai Stewart, Nick Haradhvala et autres
Abstract Women who harbor germline heterozygous mutations of BRCA1 or BRCA2 have a high risk of breast cancer. Our previous study showed that patient-derived, ostensibly normal BRCA2mut/+ luminal progenitor (LP) cells are more prone to exhibit sub-chromosomal copy number variations and associated …
2025
conference-abstract
OpenAlex
Zuen Ren, Kiran Kurmi, Tiziano Bernasocchi, Eric F. Zaniewski et autres
Abstract Drug resistance is the leading cause of neoadjuvant chemotherapy (NAC) failure to achieve pathological complete response (pCR) in more than 40% of patients with triple negative breast cancer (TNBC). Thus, understanding the potential drug resistance mechanisms in TNBC patients is a …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Chenxu Guo, Sheng Sun, Nayana Thimmiah, Ilze Smidt et autres
Abstract The tumor immune microenvironment (TIME) is a critical driver for the progression of triple-negative breast cancer (TNBC), directly impacting patient prognosis and treatment response. One emerging mechanism underlying immune evasion in TNBC involves extracellular vesicles (EVs), which act as carriers of …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Nicole Peiris, Simona Cristea, Mengran Zhang, Siang‐Boon Koh et autres
Abstract Triple-Negative Breast Cancer (TNBC) is an aggressive breast cancer subset, which lacks expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor-2. This subset of breast cancer disproportionately affects Black and African American women and improving TNBC treatment options …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Zuen Ren, Po‐Han Lin, Siang‐Boon Koh, Kai Stewart et autres
Abstract Women who harbor germline heterozygous mutations of BRCA1 or BRCA2 have a high risk of breast cancer. Our previous study showed that patient-derived, ostensibly normal BRCA2mut/+ luminal progenitor (LP) cells are more prone to exhibit sub-chromosomal copy number variations and associated …
us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Timothy S. Breton, William G. B. Sampson, Ben Clifford, Anyssa M. Phaneuf et autres
The SREB (Super-conserved Receptors Expressed in Brain) family of G protein-coupled receptors is highly conserved across vertebrates and consists of three members: SREB1 (orphan receptor GPR27), SREB2 (GPR85), and SREB3 (GPR173). Ligands for these receptors are largely unknown or only recently identified, …
us
(code pays fourni par la source)